Frailty biomarkers in humans and rodents: Current approaches and future advances.

Authors:
Alice E Kane
Alice E Kane
National Institutes of Health
United States
David A Sinclair
David A Sinclair
Harvard Medical School
Boston | United States

Mech Ageing Dev 2019 Jun 17;180:117-128. Epub 2019 Apr 17.

Department of Genetics, Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The University of New South Wales, Sydney, Australia. Electronic address:

Even though they would have great benefit across research and clinical fields, currently there are no accepted biomarkers of frailty. Cross-sectional studies in humans have identified promising candidates including inflammatory markers such as IL-6, immune markers such as WBC count, clinical markers such as albumin, endocrine markers such as vitamin D, oxidative stress markers such as isoprostanes, proteins such as BDNF and epigenetic markers such as DNA methylation, but there are limitations to the current state of the research. Future approaches to the identification of frailty biomarkers should include longitudinal studies, studies using animal models of frailty, studies incorporating novel biomarkers combined into composite panels, and studies investigating sex differences and potential overlap between markers of biological age and frailty.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00476374193003
Publisher Site
http://dx.doi.org/10.1016/j.mad.2019.03.007DOI Listing
June 2019
5 Reads

Publication Analysis

Top Keywords

frailty biomarkers
8
markers
7
frailty
5
studies
5
epigenetic markers
4
bdnf epigenetic
4
dna methylation
4
markers dna
4
limitations current
4
future approaches
4
state future
4
current state
4
proteins bdnf
4
methylation limitations
4
stress markers
4
markers albumin
4
clinical markers
4
count clinical
4
wbc count
4
albumin endocrine
4

Similar Publications